IFNAR1 and myeloid sarcoma: The exact extent to which microglial IFNα/β contributes to IFNAR1-dependent alleviation of EAE remains to be determined and the question how increasing knowledge on CNS-innate IFN-driven regulatory programs could be translated into potential therapies for MS is still unanswered.